Latest Stock Market News

The stock quoted a 52-week high price of Rs 2550.95 and a 52-week low of Rs 1660.65.

The Nifty Realty index closed 1.2 per cent up at 651.5.

On the technical charts, the RSI of the stock stood at 64.91.

Promoters held 51.46 per cent stake in the company as of 30-Sep-2023, while FII and DII ownership stood at 11.65 per cent and 4.55 per cent, respectively.

The stock rose from Rs 3910 registered on 27 October to Rs 4335 which is the intraday record high as of 6 November translating into an upside of over 10% in a week.

Gland Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2023.

A total of 277,001 shares changed hands on the counter till time (IST).

“Pharma sector can be a very good proxy to a weak rupee. Rather than IT, be in pharma to play a weak rupee. That has been a splendid outperforming sector. Cipla, Sun Pharma, Aurobindo are just coming of age and I still continue to think Lupin can be a huge outperformer.”

RSI or the relative strength index computes the ratio of the recent upward traction in the stock price movement relative to its absolute price movement.

CLSA downgraded Bharat Forge to sell and Morgan Stanley maintained an overweight rating on Nykaa.